[October 21, 2025, Suzhou, China] Suzhou Siran Biot≤echnology announces SA1211 was approved for Phase I clinical trial in China (Approval Number: 20'25LP02762), for the treatment of chronic hepatitis B (CHB).  SA1211 is the first d≤ual-targeting siRNA drug which silences mRNA of HBV and PD-L1 on the infected hepatocytes.  I©t is also the first single molecule dual-targeting∞ siRNA that got IND approval in the world.

CHB is a major challenge of public health in the world.  The goal f↓or new CHB therapeutics is the functional cure, i.e., to eliminate HBV DNA and HBsAg in serum witho≥ut viral relapse.  Although tremendous progresses have been made for t±he HBV viral clearance, high percentage of viral rebound is the maj&or challenge for the first-line drugs as well as the most promising new drugs in clinical trials×.  To address that, SiranBio invented two siRNA molecules: the first one degrades HBV≤ mRNA, and the second one silences the PD-L1 mRNA in hepatocytes.  We furthe"r connected those two molecules into a dimer based on our proprietary dual-targetinβg platform technology, and achieved a single molecule that has the pharmacodynamics of λcombo treatment: eliminates HBV and restores acquire↓d immune response.  In pre-clinical studies, >80% of mice were functional cured w§ith single injection of SA1211.  Those results were orally presented in AASLD, and was ac•claimed widely.

The IND approval of SA1211 may provide a novel approach for ‍the functional cure of CHB.  SA1211 is expected to provide a novel therap↕eutic approach for the functional cure of chronic hepatitis B. The dual-targeting siRNA platform ₹technology can be applied in many other chronic diseases which involve the modulation of multΩiple targets simultaneously.  SiranBio is working on several dual-target as well as ex'trahepatic delivered siRNA drugs and pushing them to clinical stages. In CMC ←studies, SiranBio and Hongene Bioengineering worked together to overcome huge challenges in the δprocess chemistry and analytical method development for dual-targeting↕ siRNA, laying a solid foundation to support SA1211 and future dual-t©argeting siRNAs into clinical trials and commercialization.

About SiranBio

SiranBio was founded in Biobay of Suzhou in May 2022.  We are a Biotech company focusing on si$RNA drug discovery.  Our core team is compose©d of top scientists and industrial experts with many years of experiences in the related  fields. We have received several awards including Suzhou Industri♥al Park Leading Enterprise and Gusu Leading Enterprise. 

We have independently developed cutting-edge and proprietary platform technol‌ogies that covers the full spectrum of nucleic acid drug discovery, including eSAFE chemπical modification, the Stork-W dual-targeting platform, and ‌intra- and extrahepatic delivery technologies.  We dλeveloped drug pipelines for viral infections, cardiovascular and m♥etabolic diseases, and have set up multiple licensing☆ and collaborations with renowned domestic and international pharmaceutical companiλes. Committed to patient-centered innovation, SiranBio strives to innovate best siRNA drugs for unm®et clinical needs and better health for mankind.